Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

GSK's severe asthma therapy Nucala could find a new lease ... and Regeneron's big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab) - which ...

The GWAS summary data for asthma and allergic rhinitis were obtained from UK Biobank ... such as baricitinib (JAK1/2 inhibitor) and dupilumab (anti-IL-4Rα), which have been shown to have potential ...

The Nose Knows: Nasal Swab Detects Asthma Type in Kids Jan. 2, 2025 — A new, non-invasive nasal swab test for kids that diagnoses specific asthma subtype, or endotype, could help clinicians ...

Dec. 25, 2024 — A new method of scanning lungs is able to show in real time how air moves in and out of the lungs as people take a breath in patients with asthma, chronic obstructive pulmonary ...

Medically reviewed by Brendan Camp, MD Hives and eczema are two of the most common skin disorders. Hives, clinically known as ...

Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the history of present illness for a case of severe asthma with nasal polyps: "Patient is a 45 year-old male with a past medical ...